RecruitingPhase 1NCT06740799
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
A Phase 1, Multicenter, Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Quizartinib in Subjects With Severe Impaired Hepatic Function
Sponsor
Daiichi Sankyo
Enrollment
12 participants
Start Date
Sep 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Voluntarily consents to participate in this study and provides written informed consent before the start of any study-specific procedures.
- Male and female subjects 18 to 75 years of age (inclusive), with a body mass index (BMI) of 18 kg/m2 to 37 kg/m2 (inclusive) with a minimum body weight of 40 kg at Screening.
- In females, documented surgical sterilization (ie, documented hysterectomy, bilateral tubal ligation, or bilateral salpingo-oophorectomy, Essure® with hysterosalpingogram \[documentation to confirm tubal occlusion 12 weeks after procedure\]), postmenopausal status for at least 1 year (follicle stimulating hormone \[FSH\] > 40 mIU/mL serum and estradiol <40 pg/mL \[<147 pmol/L\] at Screening), or agreement to have a sterile male partner, or agreement to use 1 of the means of contraception from Screening until 7 months after the dose of quizartinib 4. In females, agreement to not retrieve eggs/ova via assisted reproductive technology (ART) either for their own use or donation while on the study or for 7 months after the last dose of study drug, whichever is later.
- \. In males, documented surgical sterilization, sexual abstinence, or agreement to use 1 of the means of contraception from Screening until 4 months after the dose of quizartinib 6. In males, agreement to avoid sperm donation for 4 months after the dose of quizartinib
Exclusion Criteria6
- Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormality except hepatic impairment) that could interfere with safety, obtaining informed consent, compliance to the study procedures, or the validity of the study results.
- In the opinion of the investigator, history of a clinically significant illness within 4 weeks prior to administration of quizartinib.
- Subjects with primary biliary cirrhosis or primary sclerosing cholangitis.
- Subjects with history of Gilbert's syndrome.
- Presence or history of clinically severe adverse reaction to any drug or known hypersensitivity to any of the ingredients (including inactive ingredients) of quizartinib.
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (with the exception of appendectomy, hernia repair, and/or cholecystectomy).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGQuizartinib
Participants will receive a single oral dose of 30 mg
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06740799
Related Trials
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
NCT072488393 locations
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
NCT070233543 locations
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
NCT071441114 locations
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
NCT075467604 locations
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
NCT072693013 locations